Ceri E Stewart1, Ian Sayers. 1. Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, NG7 2UH, UK.
Abstract
PURPOSE: The plasminogen system plays many roles in normal epithelial cell function, and components are elevated in diseases, such as cancer and asthma. The relative contribution of each component to epithelial function is unclear. We characterized normal cell function in airway epithelial cells with increased expression of selected pathway components. METHODS: BEAS-2B R1 bronchial epithelial cells stably overexpressing membrane urokinase plasminogen activator receptor (muPAR), soluble spliced uPAR (ssuPAR), the ligand (uPA) or inhibitors (PAI1 or PAI2), were characterized for pathway expression. Cell function was examined using proliferation, apoptosis, and scratch wound assays. A549 alveolar epithelial cells overexpressing muPAR were similarly characterized and downstream plasmin activity, MMP-1, and MMP-9 measured. RESULTS: Elevated expression of individual components led to changes in the plasminogen system expression profile, indicating coordinated regulation of the pathway. Increased muPAR expression augmented wound healing rate in BEAS-2B R1 and attenuated repair in A549 cells. Elevated expression of other system components had no effect on cell function in BEAS-2B R1 cells. This is the first study to investigate activity of the splice variant ssuPAR, with results suggesting that this variant plays a limited role in epithelial cell function in this model. CONCLUSIONS: Our data highlight muPAR as the critical molecule orchestrating effects of the plasminogen system on airway epithelial cell function. These data have implications for diseases, such as cancer and asthma, and suggest uPAR as the key therapeutic target for the pathway in approaches to alter epithelial cell function.
PURPOSE: The plasminogen system plays many roles in normal epithelial cell function, and components are elevated in diseases, such as cancer and asthma. The relative contribution of each component to epithelial function is unclear. We characterized normal cell function in airway epithelial cells with increased expression of selected pathway components. METHODS: BEAS-2B R1 bronchial epithelial cells stably overexpressing membrane urokinase plasminogen activator receptor (muPAR), soluble spliced uPAR (ssuPAR), the ligand (uPA) or inhibitors (PAI1 or PAI2), were characterized for pathway expression. Cell function was examined using proliferation, apoptosis, and scratch wound assays. A549 alveolar epithelial cells overexpressing muPAR were similarly characterized and downstream plasmin activity, MMP-1, and MMP-9 measured. RESULTS: Elevated expression of individual components led to changes in the plasminogen system expression profile, indicating coordinated regulation of the pathway. Increased muPAR expression augmented wound healing rate in BEAS-2B R1 and attenuated repair in A549 cells. Elevated expression of other system components had no effect on cell function in BEAS-2B R1 cells. This is the first study to investigate activity of the splice variant ssuPAR, with results suggesting that this variant plays a limited role in epithelial cell function in this model. CONCLUSIONS: Our data highlight muPAR as the critical molecule orchestrating effects of the plasminogen system on airway epithelial cell function. These data have implications for diseases, such as cancer and asthma, and suggest uPAR as the key therapeutic target for the pathway in approaches to alter epithelial cell function.
Authors: Eric K Chu; Jason Cheng; John S Foley; Brigham H Mecham; Caroline A Owen; Kathleen J Haley; Thomas J Mariani; Isaac S Kohane; Daniel J Tschumperlin; Jeffrey M Drazen Journal: Am J Respir Cell Mol Biol Date: 2006-06-22 Impact factor: 6.914
Authors: Lance Cohen; Xueping E; Jaime Tarsi; Thiruvamoor Ramkumar; Todd K Horiuchi; Rebecca Cochran; Steve DeMartino; Kenneth B Schechtman; Iftikhar Hussain; Michael J Holtzman; Mario Castro Journal: Am J Respir Crit Care Med Date: 2007-04-26 Impact factor: 21.405
Authors: I H Heijink; S M Brandenburg; J A Noordhoek; D S Postma; D-J Slebos; A J M van Oosterhout Journal: Eur Respir J Date: 2009-09-09 Impact factor: 16.671
Authors: K Fischer; V Lutz; O Wilhelm; M Schmitt; H Graeff; P Heiss; T Nishiguchi; N Harbeck; H Kessler; T Luther; V Magdolen; U Reuning Journal: FEBS Lett Date: 1998-10-30 Impact factor: 4.124
Authors: N Falkenberg; N Anastasov; K Rappl; H Braselmann; G Auer; A Walch; M Huber; I Höfig; M Schmitt; H Höfler; M J Atkinson; M Aubele Journal: Br J Cancer Date: 2013-10-15 Impact factor: 7.640
Authors: Chelsea L Loughner; Elspeth A Bruford; Monica S McAndrews; Emili E Delp; Sudha Swamynathan; Shivalingappa K Swamynathan Journal: Hum Genomics Date: 2016-04-21 Impact factor: 4.639
Authors: Michael A Portelli; Mateusz Siedlinski; Ceri E Stewart; Dirkje S Postma; Maartje A Nieuwenhuis; Judith M Vonk; Peter Nurnberg; Janine Altmuller; Miriam F Moffatt; Andrew J Wardlaw; Stuart G Parker; Martin J Connolly; Gerard H Koppelman; Ian Sayers Journal: FASEB J Date: 2013-11-18 Impact factor: 5.191